HorizonTherapeutics.com Horizon at a Glance
Focused on going to Personally invested in incredible lengths for our our patients wherever patient populations they are in their journey
More than Our medicines treat rare, Global headquarters in Dublin, 1,800 employees autoimmune and severe Ireland, with U.S. operations inflammatory diseases in Deerfield, Illinois, South San Francisco, California, and Gaithersburg and Rockville, Maryland
Proprietary and Confidential Property of Horizon 2 We Are a Science-Based Organization Addressing Unmet Needs for Underserved Patients
RARE DISEASE AUTOIMMUNE SEVERE INFLAMMATORY Rare diseases pose a significant and unique Autoimmune diseases are the result of an Severe inflammatory diseases are challenge in medicine and for the care of individual’s immune system attacking its characterized by inflammation in the body, these small populations of patients. Only 5 own healthy cells and tissue. These diseases including the joints, muscles and other percent of the 7,000 known rare diseases often involve autoreactive immune cells bodily systems. This inflammation can cause have approved treatments1. that may create autoantibodies and result substantial and chronic pain, reduced in recurring bouts of disease flares followed mobility and difficulty in daily life. by periods of remission.
Out of 12 medicines for the treatment of Programs 8 RARE DISEASES 27 in DEVELOPMENT
1 Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet Journal of Rare Diseases. 2011;6(1):49. doi:10.1186/1750-1172-6-49.
Proprietary and Confidential Property of Horizon 3 Updated September 29, 2021 A Pipeline Built With Purpose
Program Potential Indication Preclinical Phase 1 Phase 2 Phase 3
Combination with Immunomodulation in Uncontrolled KRYSTEXXA Gout* Horizon is exploring the Myasthenia Gravis potential of its on-market UPLIZNA IgG4-Related Disease medicines to identify paths for new treatment methods Kidney Transplant Desensitization and improve patient Diffuse Cutaneous Systemic Sclerosis outcomes. HZN-825 Idiopathic Pulmonary Fibrosis
Focal Segmental Glomerulosclerosis • Evaluating efficacy and Kidney Transplant Rejection Dazolipeb safety of KRYSTEXXA in (HZN-4920) Rheumatoid Arthritis broader patient populations – PROTECT Sjögren’s Syndrome (nephrology) and Alopecia Areata retreatment (ADVANCE) Dermatomyositis Daxdilimab • Exploring the patient Discoid Lupus Erythematosus (HZN-7734) experience with Lupus Nephritis KRYSTEXXA – monthly dosing (FORWARD) and Systemic Lupus Erythematosus shorter infusion Diffuse Cutaneous Systemic Sclerosis durations (AGILE) TEPEZZA Subcutaneous Administration • Quantifying the impact HZN-1116 Autoimmune Diseases of TEPEZZA for patients Arrowhead with chronic Thyroid Eye Disease HZN-003 Next-Gen Uncontrolled Gout
HZN-007 *Phase 4 HemoShear Novel Gout Targets
Proprietary and Confidential Property of Horizon 4 Our Commitment Beyond Our Medicines We Participate, Listen and Learn with Our Disease Communities
+60 +1,000
Patient advocacy group Employees take part in hundreds partnerships globally of advocacy events around the world
Proprietary and Confidential Property of Horizon 6 We Create Change in Our Community: Annual Impact
+60 $1B $3.7M
Non-profits Provided in COVID-19 relief supported patient support
4 $20M+ $500K+ 11
Pillars of giving in In support Racial equity Of the 17 United healthcare, STEAM, of our communities response Nations Sustainable environmental Development Goals sustainability and supported innovation
Proprietary and Confidential Property of Horizon 7 “Going above and beyond for patients is what we do every day. It is at the core of our company culture and reflects my own experience as a patient.”
Tim Walbert Chairman, President and CEO
Working At Horizon Isn’t Just A Job. It’s Personal. Thank you
HorizonTherapeutics.com